Groundbreaking Updates on Melanoma and Advanced Endometrial Cancer from NYU Langone at ASCO 2024

Introduction

Researchers from NYU Langone Health's Perlmutter Cancer Center presented significant updates at the 2024 American Society of Clinical Oncology (ASCO) Annual Conference in Chicago, addressing major advances in cancer treatment.

Long-term Efficacy of mRNA Vaccine for Metastatic Melanoma

One of the key presentations focused on a three-year follow-up study of an individualized neoantigen mRNA vaccine, mRNA-4157/V940, combined with the immunotherapy drug pembrolizumab for treating metastatic melanoma. Results showed a considerable increase in recurrence-free survival rates and overall survival among patients receiving the combination therapy.

Compared to those receiving only pembrolizumab, patients treated with both pembrolizumab and mRNA-4157/V940 had significantly better outcomes, with a 74.8% long-term recurrence-free survival rate versus 55.6%, and an overall survival rate of 96.0% compared to 90.2%. This study highlights the potential of the mRNA vaccine in melanoma treatment.

Understanding Treatment Patterns in Advanced Endometrial Cancer

Another important study examined the treatment patterns and outcomes in patients with advanced endometrial cancer. Led by Dr. Bhavana Pothuri, the study analyzed data from 1,441 patients to assess the use of new therapies and MMR/MSI testing.

Findings indicated that while MMR/MSI testing is commonly performed, less than 50% of patients received new therapeutic options. This points to a need for further research and education to promote the adoption of innovative treatments for advanced endometrial cancer.

Promising Noninvasive Treatment for Recurrent Glioblastoma

A study led by Dr. Dimitris G. Placantonakis explored the use of sonodynamic therapy for treating recurrent glioblastoma, a deadly brain tumor with limited treatment options. This noninvasive technique combines a drug with focused ultrasound to target and destroy tumor cells.

The ongoing phase 1/2 study aims to determine the maximum tolerable dose and assess the treatment's safety and efficacy. Preliminary results show promise, offering hope for a new approach to managing recurrent glioblastoma without the need for surgical intervention.

Conclusion

The presentations at ASCO 2024 underscore the Perlmutter Cancer Center's dedication to advancing cancer treatment and improving patient outcomes. These studies highlight the importance of ongoing research and innovation in oncology.